Published in Neurology on February 09, 2010
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Arguments for the sake of endophenotypes: examining common misconceptions about the use of endophenotypes in psychiatric genetics. Am J Med Genet B Neuropsychiatr Genet (2014) 1.08
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer's disease. Mol Neurodegener (2011) 1.04
Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. Mol Neurodegener (2012) 1.02
Association of common KIBRA variants with episodic memory and AD risk. Neurobiol Aging (2010) 0.94
Constructing endophenotypes of complex diseases using non-negative matrix factorization and adjusted rand index. PLoS One (2012) 0.81
A computational method based on the integration of heterogeneous networks for predicting disease-gene associations. PLoS One (2011) 0.80
Allele-specific behavior of molecular networks: understanding small-molecule drug response in yeast. PLoS One (2013) 0.79
Association between variants in IDE-KIF11-HHEX and plasma amyloid β levels. Neurobiol Aging (2010) 0.79
LRRTM3 interacts with APP and BACE1 and has variants associating with late-onset Alzheimer's disease (LOAD). PLoS One (2013) 0.79
Linking protective GAB2 variants, increased cortical GAB2 expression and decreased Alzheimer's disease pathology. PLoS One (2013) 0.78
Next frontiers in the genetic epidemiology of Alzheimer's disease. Eur J Epidemiol (2012) 0.76
Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Sci Data (2016) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
A genome-wide association study of global gene expression. Nat Genet (2007) 22.98
The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry (2003) 21.70
Genome-wide associations of gene expression variation in humans. PLoS Genet (2005) 17.27
Mapping determinants of human gene expression by regional and genome-wide association. Nature (2005) 17.24
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Genetic inheritance of gene expression in human cell lines. Am J Hum Genet (2004) 8.97
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry (2006) 6.68
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet (2008) 5.93
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet (2008) 4.66
Abundant raw material for cis-regulatory evolution in humans. Mol Biol Evol (2002) 4.37
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet (2009) 3.54
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science (2000) 3.16
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
Neuroimaging endophenotypes: strategies for finding genes influencing brain structure and function. Hum Brain Mapp (2007) 2.36
Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci (2000) 2.22
Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav (2006) 2.12
Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology (1996) 2.00
Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett (1994) 1.99
Effects of genome-wide heterozygosity on a range of biomedically relevant human quantitative traits. Hum Mol Genet (2007) 1.77
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Genome-wide association study of biochemical traits in Korcula Island, Croatia. Croat Med J (2009) 1.45
Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care (2001) 0.97
Expression analyses of 27 DNA repair genes in astrocytoma by TaqMan low-density array. Neurosci Lett (2006) 0.96
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell (1996) 11.22
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell (1999) 8.07
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 7.30
A meta-analysis of fear appeals: implications for effective public health campaigns. Health Educ Behav (2000) 6.72
Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet (1997) 6.69
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
A clinical trial of a chest-pain observation unit for patients with unstable angina. Chest Pain Evaluation in the Emergency Room (CHEER) Investigators. N Engl J Med (1998) 5.67
High-throughput variation detection and genotyping using microarrays. Genome Res (2001) 5.24
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
Affective disorders and suicide risk: a reexamination. Am J Psychiatry (2000) 4.63
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00
Falls by elderly people at home: prevalence and associated factors. Age Ageing (1988) 3.92
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology (2000) 3.84
Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology (2010) 3.83
Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain (2007) 3.82
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet (2000) 3.64
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
A neuronal antigen in the brains of Alzheimer patients. Science (1986) 3.49
The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol (1991) 3.45
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
The effect of intragenic recombination on the number of alleles in a finite population. Genetics (1978) 3.27
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology (2007) 3.24
Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry (1991) 3.21
Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J Biol Chem (1995) 3.17
ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet (2000) 3.17
Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA (2000) 3.15
Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology (1989) 3.12
Levels of customary physical activity among the old and the very old living at home. J Epidemiol Community Health (1988) 3.07
Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine (2010) 3.06
The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology (2012) 3.01
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology (2007) 2.93
Decoding the ancient Greek astronomical calculator known as the Antikythera Mechanism. Nature (2006) 2.92
BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron (2004) 2.90
Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem (2000) 2.89
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 2.88
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science (1992) 2.82
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Haplotype mapping and sequence analysis of the mouse Nramp gene predict susceptibility to infection with intracellular parasites. Genomics (1994) 2.80
A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell (1993) 2.80
Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet (1995) 2.77
Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet (2002) 2.77
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Parents' beliefs about vaccination: the continuing propagation of false contraindications. BMJ (1989) 2.71
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital 'Utstein style'. American Heart Association. Circulation (1997) 2.68
Adhesion formation after previous caesarean section-a meta-analysis and systematic review. BJOG (2010) 2.66
Psychological markers in the detection of autism in infancy in a large population. Br J Psychiatry (1996) 2.64
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet (1989) 2.56
Anxiety caused by a short-life hypnotic. Br Med J (Clin Res Ed) (1982) 2.51
The King-Devick test as a determinant of head trauma and concussion in boxers and MMA fighters. Neurology (2011) 2.51
Complications of use of intrauterine devices among HIV-1-infected women. Lancet (1998) 2.50